Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method

Anant Ramaswamy; Sujay Srinivas; Viraj Lavingia; Mounika Boppana; Chakor Vora; Randeep Singh; M. Vamshi Krishna; Amish Vora; Sujith Kumar Mullapally; Prabhat Bhargava; Vinayak Maka; Gautam Goyal; Vivek Agarwala; Ashay Karpe; Jimmy Mirani; S Krupa Shankar; Tanmoy Kumar Mandal; Sourav Kumar Mishra; Nisar Ahmad Syed; Atul Sharma; Shasanka Sekhar Das; Soumya Surath Panda; Pradip Kumar Mondal; Amit Kumar; Shekar Patil; Rakesh Pinninti; Ajoy Oommen John; Murtaza Bohra; Rejiv Rajendranath; Sudeep Das; Sumit Goyal; Rakesh M. P.; Krishnakumar Rathnam; Amol Patel; Boman Dhabhar; Aditi Thanky; Vipul Doshi; Akhil Kapoor; Nishitha Shetty; Davinder Paul; Jacob George; Akshay D. Baheti; Rahul Krishnatry; Vikas Ostwal

doi:10.1055/s-0045-1809380

South Asian Journal of Cancer, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0045-1809380

Consensus

Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method

Anant Ramaswamy

¹Department of Medical Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India

,

Sujay Srinivas

²Department of Medical Oncology, Bharath Hospital, Kottayam, Kerala, India

,

Viraj Lavingia

³Department of Medical Oncology, Shalby Hospital, Ahmedabad, Gujarat, India

,

Mounika Boppana

⁴Department of Medical Oncology and Haematoncology, Krishna Institute of Medical Sciences (KIMS) Hospital, Secunderabad, Hyderabad, Telangana, India

,

Chakor Vora

⁵Department of Medical Oncology, Sassoon General Hospital, Pune, India

,

Randeep Singh

⁶Department of Medical and Hemato-Oncology, Narayana Health, Gurugram, Haryana, India

,

M. Vamshi Krishna

⁷Department of Medical Oncology and Haematology, Institute of Oncology AIG Hospitals, Hyderabad, Telangana, India

,

Amish Vora

⁸Department of Medical Oncology, H.O.P.E. Oncology Clinic, New Delhi, India

,

Sujith Kumar Mullapally

⁹Department of Medical Oncology, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India

,

Prabhat Bhargava

¹Department of Medical Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India

,

Vinayak Maka

¹⁰Department of Medical Oncology, Ramaiah Medical College, Bengaluru, Karnataka, India

,

Gautam Goyal

¹¹Department of Medical Oncology and Hemato-Oncology, Max Super Specialty Hospital, Mohali, India

,

Vivek Agarwala

¹²Department of Medical Oncology and Hemato-Oncology, Narayana Health, Kolkata, Bengal, India

,

Ashay Karpe

¹³Department of Medical Oncology, Sunrise Oncology Centre, Mumbai, Maharashtra, India

,

Jimmy Mirani

¹⁴Department of Medical Oncology, Wockhardt Hospital, Mumbai Central, Maharashtra, India

,

S Krupa Shankar

¹⁵Department of Medical Oncology, NSR CanKure Center, Coimbatore, Tamil Nadu, India

,

Tanmoy Kumar Mandal

¹⁶Department of Medical Oncology, AMRI Hospital, Dhakuria, Kolkata, West Bengal, India

,

Sourav Kumar Mishra

¹⁷Department of Medical Oncology/Hematology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India

,

Nisar Ahmad Syed

¹⁸Department of Medical Oncology, Sheri Kashmir Institute of Medical Sciences SKIMS, Soura, Jammu and Kashmir, India

,

Atul Sharma

¹⁹Department of Medical Oncology and Hemato-Oncology, Max Super Specialty Hospital, Saket, New Delhi, India

,

Shasanka Sekhar Das

²⁰Department of Medical Oncology, HCG EKO Cancer Center, Kolkata, West Bengal, India

,

Soumya Surath Panda

²¹Department of Medical Oncology, IMS & SUM Hospital, Bhubaneswar, Odisha, India

,

Pradip Kumar Mondal

²²Department of Medical Oncology, Medica Super Specialty Hospital Mukundapur, Kolkata, West Bengal, India

,

Amit Kumar

²³Department of Medical Oncology and Hemato-Oncology, Jay Prabha Medanta Super Specialty Hospital, Patna, Bihar, India

,

Shekar Patil

²⁴Department of Medical Oncology, HCG Hospital Bangalore, Karnataka, India

,

Rakesh Pinninti

²⁵Department of Medical Oncology, Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, Telangana, India

,

Ajoy Oommen John

²⁶Department of Medical Oncology, CMC Vellore, Ranipet Campus, Vellore, Tamil Nadu, India

,

Murtaza Bohra

²⁷Department of Medical Oncology, National Cancer Institute, Nagpur, India

,

Rejiv Rajendranath

²⁸Department of Medical Oncology, Integrated Cancer Care Group, GEM Hospital, Institute of Gastroenterology and Laparoscopy, Chennai, Tamil Nadu, India

,

Sudeep Das

²⁹Department of Medical and Hemato-Oncology, Medica Superspecialty Hospital, Mukundapur, Kolkata, West Bengal, India

,

Sumit Goyal

³⁰Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Delhi, India

,

Rakesh M. P.

³¹Department of Medical Oncology, Amrita Institute of Medical Sciences, Kerala, India

,

Krishnakumar Rathnam

³²Department of Medical Oncology, Meenakshi Mission Hospital, Chinthamani Madurai, Tamil Nadu, India

,

Amol Patel

³³Department of Medical Oncology, Command Hospital, Central Command, Lucknow, Uttar Pradesh, India

,

Boman Dhabhar

³⁴Department of Medical Oncology, Fortis Hospital Mulund, Mumbai, Maharashtra, India

,

Aditi Thanky

³⁵Department of Medical Oncology, Sterling Hospital, Rajkot, Gujarat, India

,

Vipul Doshi

³⁶Department of Medical Oncology, Solapur Cancer Centre, Solapur, India

,

Akhil Kapoor

³⁷Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Homi Bhabha National Institute, Varanasi

,

Nishitha Shetty

³⁸Department of Medical Oncology, Father Muller Medical College, Mangalore, Karnataka, India

,

Davinder Paul

³⁹Department of Medical Oncology, Fortis Hospital, Ludhiana, Punjab, India

,

Jacob George

⁴⁰Department of Medical Oncology, Manipal Hospital, Panaji, Goa, India

,

Akshay D. Baheti

⁴¹Department of Radiodiagnosis, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India

,

Rahul Krishnatry

⁴²Department of Radiation Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India

,

Vikas Ostwal

¹Department of Medical Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India

› Institutsangaben

Abstract

Background

Colorectal cancer (CRC) is one of the most common malignancies across the world and is the fourth most common cancer among men in India as per the Global Cancer Observatory (GLOBOCAN) data 2020. Available data suggest that approximately 30% of patients present with advanced/metastatic CRC (mCRC). This publication summarizes the latest evidence with cognizance of the unique challenges faced in India by medical oncologists treating mCRC.

Methods

A panel of 38 medical oncologists held a meeting in February 2023 and reviewed the evidence available for the management of mCRC. The meeting concentrated on the recognition and management of mCRC with a focus on systemic therapeutic approaches. A literature review of these aspects of management leads to the formation of consensus statements with the level of evidence and grades of recommendation. Statements were evaluated by the modified Delphi method.

Key Content and Findings

The panel comprising 38 experts formulated 51 consensus statements with regard to the management of mCRC, including oligometastatic CRC, unresectable CRC, as well as various systemic therapeutic options. Resource-constrained scenarios, specifically with regard to the economic constraints and availability of drugs in India, were evaluated as part of the statements.

Conclusion

Our consensus statements offer practical, yet evidence-based management guidelines for treating mCRC in the Indian context. Stratifying and recommending treatment options in a resource-constrained scenario is an important aspect of these statements.

Keywords

India specific - metastatic colorectal cancer - modified Delphi consensus

Volltext

Referenzen

References
1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
2 Asthana S, Khenchi R, Labani S. Incidence of colorectal cancers in India: a review from population-based cancer registries. Curr Med Res Pract 2021; 11 (02) 91
3 Mathew Thomas V, Baby B, Wang K. et al. Trends in colorectal cancer incidence in India. J Clin Oncol 2020; 38 (15, Suppl): e16084-e16084
4 Patil PS, Saklani A, Gambhire P. et al. Colorectal cancer in India: an audit from a tertiary center in a low prevalence area. Indian J Surg Oncol 2017; 8 (04) 484-490
5 Sharma V, Sharma A, Raina V. et al. Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center. BMC Cancer 2021; 21 (01) 630
6 Ramaswamy A, Babu V, Kothari R. et al. Treatment of metastatic colorectal cancers in resource-constrained low- and middle-income countries (LMICS) scenario-outcomes, practice patterns, and commentary on treatment costs. South Asian J Cancer 2022; 11 (04) 293-298
7 Cervantes A, Adam R, Roselló S. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34 (01) 10-32
8 Morris VK, Kennedy EB, Baxter NN. et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 2023; 41 (03) 678-700
9 Sirohi B, Shrikhande SV, Perakath B. et al. Indian Council of Medical Research consensus document for the management of colorectal cancer. Indian J Med Paediatr Oncol 2014; 35 (03) 192-196
10 Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis 2010; 51 (10) 1147-1156
11 Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352 (07) 734-735
12 Leufkens AM, van den Bosch MAAJ, van Leeuwen MS, Siersema PD. Diagnostic accuracy of computed tomography for colon cancer staging: a systematic review. Scand J Gastroenterol 2011; 46 (7-8(: 887-894
13 Dighe S, Blake H, Koh MD. et al. Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer. Br J Surg 2010; 97 (09) 1407-1415
14 Dighe S, Purkayastha S, Swift I. et al. Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. Clin Radiol 2010; 65 (09) 708-719
15 Schnitzer ML, Froelich MF, Gassert FG. et al. Follow-up 18F-FDG PET/CT versus contrast-enhanced CT after ablation of liver metastases of colorectal carcinoma - a cost-effectiveness analysis. Cancers (Basel) 2020; 12 (09) 2432
16 Israel O, Kuten A. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. J Nucl Med 2007; 48 (Suppl. 01) 28S-35S
17 Abdel-Nabi H, Doerr RJ, Lamonica DM. et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206 (03) 755-760
18 Nahas CSR, Akhurst T, Yeung H. et al. Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol 2008; 15 (03) 704-711
19 Fong Y, Saldinger PF, Akhurst T. et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999; 178 (04) 282-287
20 Sivesgaard K, Larsen LP, Sørensen M. et al. Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation. Eur Radiol 2018; 28 (11) 4735-4747
21 Zech CJ, Ba-Ssalamah A, Berg T. et al. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 2020; 30 (01) 370-382
22 Asato N, Tsurusaki M, Sofue K. et al. Comparison of gadoxetic acid-enhanced dynamic MR imaging and contrast-enhanced computed tomography for preoperative evaluation of colorectal liver metastases. Jpn J Radiol 2017; 35 (04) 197-205
23 Görgec B, Hansen IS, Kemmerich G. et al; CAMINO Study Group. MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial. Lancet Oncol 2024; 25 (01) 137-146
24 Ippolito D, Drago SG, Franzesi CT, Fior D, Sironi S. Rectal cancer staging: Multidetector-row computed tomography diagnostic accuracy in assessment of mesorectal fascia invasion. World J Gastroenterol 2016; 22 (20) 4891-4900
25 Torkzad MR, Påhlman L, Glimelius B. Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive review. Insights Imaging 2010; 1 (04) 245-267
26 Rafaelsen SR, Sørensen T, Jakobsen A, Bisgaard C, Lindebjerg J. Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience. Scand J Gastroenterol 2008; 43 (04) 440-446
27 Lahaye MJ, Engelen SME, Nelemans PJ. et al. Imaging for predicting the risk factors–the circumferential resection margin and nodal disease–of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR 2005; 26 (04) 259-268
28 Beets-Tan RGH. MRI in rectal cancer: the T stage and circumferential resection margin. Colorectal Dis 2003; 5 (05) 392-395
29 Taylor FGM, Quirke P, Heald RJ. et al; Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Group. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014; 32 (01) 34-43
30 Brown G, Richards CJ, Newcombe RG. et al. Rectal carcinoma: thin-section MR imaging for staging in 28 patients. Radiology 1999; 211 (01) 215-222
31 Chamlou R, Parc Y, Simon T. et al. Long-term results of intersphincteric resection for low rectal cancer. Ann Surg 2007; 246 (06) 916-921 , discussion 921–922
32 Karapetis CS, Khambata-Ford S, Jonker DJ. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359 (17) 1757-1765
33 Amado RG, Wolf M, Peeters M. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26 (10) 1626-1634
34 Peeters M, Oliner KS, Price TJ. et al. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014; 32 (3, Suppl): LBA387-LBA387
35 Van Cutsem E, Köhne CH, Láng I. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29 (15) 2011-2019
36 Maughan TS, Adams RA, Smith CG. et al; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377 (9783): 2103-2114
37 Douillard JY, Oliner KS, Siena S. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369 (11) 1023-1034
38 Peeters M, Oliner KS, Price TJ. et al. Analysis of KRAS/NRAS mutations in a Phase III Study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res 2015; 21 (24) 5469-5479
39 De Roock W, Claes B, Bernasconi D. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11 (08) 753-762
40 Tol J, Koopman M, Cats A. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360 (06) 563-572
41 Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361 (01) 98-99
42 Tie J, Gibbs P, Lipton L. et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011; 128 (09) 2075-2084
43 Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol 2015; 33 (16) 1809-1824
44 Di Nicolantonio F, Martini M, Molinari F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26 (35) 5705-5712
45 Seymour MT, Brown SR, Middleton G. et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14 (08) 749-759
46 Bokemeyer C, Van Cutsem E, Rougier P. et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48 (10) 1466-1475
47 Le DT, Uram JN, Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26) 2509-2520
48 Geiersbach KB, Samowitz WS. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 2011; 135 (10) 1269-1277
49 Ye M, Ru G, Yuan H, Qian L, He X, Li S. Concordance between microsatellite instability and mismatch repair protein expression in colorectal cancer and their clinicopathological characteristics: a retrospective analysis of 502 cases. Front Oncol 2023; 13: 1178772
50 Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016; 22 (04) 813-820
51 Goldstein J, Tran B, Ensor J. et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 2014; 25 (05) 1032-1038
52 André T, Shiu KK, Kim TW. et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383 (23) 2207-2218
53 Yonesaka K, Zejnullahu K, Okamoto I. et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3 (99) 99ra86
54 Raghav KPS, Overman MJ, Yu R. et al. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol 2016; 34 (15, Suppl): 3517-3517
55 Sartore-Bianchi A, Trusolino L, Martino C. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17 (06) 738-746
56 Meric-Bernstam F, Hurwitz H, Raghav KPS. et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2019; 20 (04) 518-530
57 Strickler JH, Cercek A, Siena S. et al; MOUNTAINEER Investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol 2023; 24 (05) 496-508
58 Bayle A, Basile D, Garinet S. et al. Next-generation sequencing targeted panel in routine care for metastatic colon cancers. Cancers (Basel) 2021; 13 (22) 5750
59 Drilon A, Laetsch TW, Kummar S. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018; 378 (08) 731-739
60 Vidal J, Muinelo L, Dalmases A. et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 2017; 28 (06) 1325-1332
61 Seymour MT, Maughan TS, Ledermann JA. et al; FOCUS Trial Investigators, National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370 (9582): 143-152
62 Koopman M, Antonini NF, Douma J. et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370 (9582): 135-142
63 Ducreux M, Malka D, Mendiboure J. et al; Fédération Francophone de Cancérologie Digestive (FFCD) 2000–05 Collaborative Group. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011; 12 (11) 1032-1044
64 Tournigand C, André T, Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22 (02) 229-237
65 Colucci G, Gebbia V, Paoletti G. et al; Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23 (22) 4866-4875
66 Díaz-Rubio E, Tabernero J, Gómez-España A. et al; Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25 (27) 4224-4230
67 Porschen R, Arkenau HT, Kubicka S. et al; AIO Colorectal Study Group. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25 (27) 4217-4223
68 Cassidy J, Clarke S, Díaz-Rubio E. et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26 (12) 2006-2012
69 Guo Y, Xiong BH, Zhang T, Cheng Y, Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest 2016; 34 (02) 94-104
70 Falcone A, Masi G, Allegrini G. et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20 (19) 4006-4014
71 Souglakos J, Mavroudis D, Kakolyris S. et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 2002; 20 (11) 2651-2657
72 Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22 (07) 1209-1214
73 Falcone A, Ricci S, Brunetti I. et al; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25 (13) 1670-1676
74 Souglakos J, Androulakis N, Syrigos K. et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94 (06) 798-805
75 Marques RP, Duarte GS, Sterrantino C. et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2017; 118: 54-62
76 Cremolini C, Loupakis F, Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16 (13) 1306-1315
77 Shahrokni A, Vishnevsky BM, Jang B. et al. Geriatric assessment, not ASA physical status, is associated with 6-month postoperative survival in patients with cancer aged ≥75 years. J Natl Compr Canc Netw 2019; 17 (06) 687-694
78 Li D, Sun CL, Kim H. et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol 2021; 7 (11) e214158
79 Antonio M, Saldaña J, Carmona-Bayonas A. et al. Geriatric assessment predicts survival and competing mortality in elderly patients with early colorectal cancer: can it help in adjuvant therapy decision-making?. Oncologist 2017; 22 (08) 934-943
80 Mohile SG, Mohamed MR, Xu H. et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet 2021; 398 (10314): 1894-1904
81 Seymour MT, Thompson LC, Wasan HS. et al; FOCUS2 Investigators, National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011; 377 (9779): 1749-1759
82 Takashima A, Hamaguchi T, Mizusawa J. et al; Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG). Oxaliplatin added to fluoropyrimidine/bevacizumab as initial therapy for unresectable metastatic colorectal cancer in older patients: a multicenter, randomized, open-label phase III trial (JCOG1018). J Clin Oncol 2024; 42 (33) 3967-3976
83 Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990; 113 (10) 779-788
84 Petrelli F, Tomasello G, Borgonovo K. et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol 2017; 3 (02) 211-219
85 Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 2017; 70: 87-98
86 Taieb J, Kourie HR, Emile JF. et al; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators. Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. JAMA Oncol 2018; 4 (07) e173695
87 Salem ME, Weinberg BA, Xiu J. et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget 2017; 8 (49) 86356-86368
88 Tejpar S, Stintzing S, Ciardiello F. et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 2017; 3 (02) 194-201
89 Boeckx N, Koukakis R, Op de Beeck K. et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol 2017; 28 (08) 1862-1868
90 Wong HL, Lee B, Field K. et al. Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clin Colorectal Cancer 2016; 15 (02) e9-e15
91 Loupakis F, Hurwitz HI, Saltz L. et al. Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC). J Clin Oncol 2018; 36 (4, Suppl): 726-726
92 Arnold D, Lueza B, Douillard JY. et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017; 28 (08) 1713-1729
93 Watanabe J, Muro K, Shitara K. et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 2023; 329 (15) 1271-1282
94 Kuboki Y, Strickler JH, Fakih M. et al. Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy. J Clin Oncol 2023. Accessed May 13, 2025 at: https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3513
95 Kopetz S, Yoshino T, Kim TW. et al. BREAKWATER: an open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 2023; 41 (16, Suppl): TPS3627-TPS3627
96 Hurwitz H, Fehrenbacher L, Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23) 2335-2342
97 Saltz LB, Clarke S, Díaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26 (12) 2013-2019
98 Cunningham D, Lang I, Marcuello E. et al; AVEX Study Investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14 (11) 1077-1085
99 Tebbutt NC, Wilson K, Gebski VJ. et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28 (19) 3191-3198
100 Hurwitz HI, Tebbutt NC, Kabbinavar F. et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013; 18 (09) 1004-1012
101 Gupta R, Meric-Bernstam F, Rothe M. et al. Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2/3 mutations: results from the TAPUR study. JCO Precis Oncol 2022; 6 (06) e2200306
102 Siena S, Di Bartolomeo M, Raghav K. et al; DESTINY-CRC01 Investigators. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 2021; 22 (06) 779-789
103 Tournigand C, Cervantes A, Figer A. et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol 2006; 24 (03) 394-400
104 Chibaudel B, Maindrault-Goebel F, Lledo G. et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27 (34) 5727-5733
105 Simkens LHJ, van Tinteren H, May A. et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385 (9980): 1843-1852
106 Hegewisch-Becker S, Graeven U, Lerchenmüller CA. et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2015; 16 (13) 1355-1369
107 Aparicio T, Ghiringhelli F, Boige V. et al; PRODIGE 9 Investigators. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol 2018; 36 (07) 674-681
108 Mohamed A, Abdallah N, Ismail H. et al. Comparative analysis of different maintenance regimens after first-line induction in patients with metastatic colorectal cancer. J Clin Oncol 2018; 36 (4, Suppl): 789-789
109 Modest DP, Rivera F, Bachet JB. et al. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: a retrospective analysis of two randomised trials. Int J Cancer 2019; 145 (02) 576-585
110 Modest DP, Karthaus M, Fruehauf S. et al. Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PANAMA trial (AIO KRK 0212). J Clin Oncol 2022; 40 (01) 72-82
111 Diaz Jr LA, Shiu KK, Kim TW. et al; KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022; 23 (05) 659-670
112 Andre T, Elez E, Van Cutsem E. et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study. J Clin Oncol 2024; 42 (3, Suppl): LBA768-LBA768
113 Patil VM, Noronha V, Menon N. et al. Low-dose immunotherapy in head and neck cancer: a randomized study. J Clin Oncol 2023; 41 (02) 222-232
114 Jethwa KR, Jang S, Mullikin TC. et al. Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. Radiother Oncol 2020; 146: 29-36
115 Barnum KJ, Weiss SA. Prognostic and predictive biomarkers in oligometastatic disease. Cancer J 2020; 26 (02) 100-107
116 Ottaiano A, Santorsola M, Circelli L. et al. Oligo-metastatic cancers: putative biomarkers, emerging challenges and new perspectives. Cancers (Basel) 2023; 15 (06) 1827
117 Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230 (03) 309-318 , discussion 318–321
118 André T, Boni C, Mounedji-Boudiaf L. et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350 (23) 2343-2351
119 Nordlinger B, Sorbye H, Glimelius B. et al; EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und–tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14 (12) 1208-1215
120 Moretto R, Rossini D, Zucchelli G. et al. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. Eur J Cancer 2020; 139: 81-89
121 Bond MJG, Bolhuis K, Loosveld OJL. et al; Dutch Colorectal Cancer Study Group. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol 2023; 24 (07) 757-771
122 Stintzing S, Modest DP, Rossius L. et al; FIRE-3 Investigators. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 2016; 17 (10) 1426-1434
123 Kanemitsu Y, Shitara K, Mizusawa J. et al; JCOG Colorectal Cancer Study Group. Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial. J Clin Oncol 2021; 39 (10) 1098-1107
124 Fiorentini G, Aliberti C, Tilli M. et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32 (04) 1387-1395
125 Ruers T, Punt C, Van Coevorden F. et al; EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012; 23 (10) 2619-2626
126 Mohamad I, Barry A, Dawson L, Hosni A. Stereotactic body radiation therapy for colorectal liver metastases. Int J Hyperthermia 2022; 39 (01) 611-619
127 Quénet F, Elias D, Roca L. et al; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (02) 256-266
128 Rougier P, Van Cutsem E, Bajetta E. et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352 (9138): 1407-1412
129 Cunningham D, Pyrhönen S, James RD. et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352 (9138): 1413-1418
130 Clarke SJ, Yip S, Brown C. et al. Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. Eur J Cancer 2011; 47 (12) 1826-1836
131 Xu RH, Muro K, Morita S. et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19 (05) 660-671
132 Rothenberg ML, Oza AM, Bigelow RH. et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21 (11) 2059-2069
133 Rothenberg ML, Cox JV, Butts C. et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19 (10) 1720-1726
134 Masi G, Salvatore L, Boni L. et al; BEBYP Study Investigators. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol 2015; 26 (04) 724-730
135 Bennouna J, Sastre J, Arnold D. et al; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14 (01) 29-37
136 Cao R, Zhang S, Ma D, Hu L. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. Med Oncol 2015; 32 (01) 325
137 Giantonio BJ, Catalano PJ, Meropol NJ. et al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25 (12) 1539-1544
138 Iwamoto S, Takahashi T, Tamagawa H. et al. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 2015; 26 (07) 1427-1433
139 Tabernero J, Yoshino T, Cohn AL. et al; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16 (05) 499-508
140 Arnold D, Fuchs CS, Tabernero J. et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 2017; 28 (12) 2932-2942
141 Peeters M, Price TJ, Cervantes A. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28 (31) 4706-4713
142 Passardi A, Scarpi E, Gelsomino F. et al. Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Sci Rep 2017; 7 (01) 10426
143 Goldberg RM, Montagut C, Wainberg ZA. et al. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open 2018; 3 (04) e000353
144 Ciardiello F, Normanno N, Martinelli E. et al; CAPRI-GOIM investigators. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol 2016; 27 (06) 1055-1061
145 Feng Q, Wei Y, Ren L. et al. Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study. Oncotarget 2016; 7 (10) 11380-11396
146 Fora AA, McMahon JA, Wilding G. et al. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan. Oncology 2013; 84 (04) 210-213
147 Liu X, George GC, Tsimberidou AM. et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer 2015; 15 (01) 713
148 Santini D, Vincenzi B, Addeo R. et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. Ann Oncol 2012; 23 (09) 2313-2318
149 Grothey A, Van Cutsem E, Sobrero A. et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381 (9863): 303-312
150 Li J, Qin S, Xu R. et al; CONCUR Investigators. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16 (06) 619-629
151 Bekaii-Saab TS, Ou FS, Ahn DH. et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 2019; 20 (08) 1070-1082
152 Masuishi T, Suzuki T, Sukawa Y. et al. Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer. Ann Oncol 2018; 29: viii156
153 Nakamura M, Yamada T, Ishiyama S. et al. Regorafenib dose escalation therapy for patients with refractory metastatic colorectal cancer (RECC Study). J Clin Oncol 2020; 38 (4, Suppl): 116-116
154 Mayer RJ, Van Cutsem E, Falcone A. et al; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372 (20) 1909-1919
155 Pfeiffer P, Yilmaz M, Möller S. et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 2020; 21 (03) 412-420
156 Fujii H, Matsuhashi N, Kitahora M. et al. Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study. Oncologist 2020; 25 (03) e469-e476
157 Van Cutsem E, Peeters M, Siena S. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25 (13) 1658-1664
158 Kim TW, Elme A, Kusic Z. et al. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer 2016; 115 (10) 1206-1214
159 Price TJ, Peeters M, Kim TW. et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014; 15 (06) 569-579
160 Suenaga M, Mizunuma N, Matsusaka S. et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 2015; 9: 3099-3108
161 Maindrault-Goebel F, Tournigand C, André T. et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004; 15 (08) 1210-1214
162 Tabernero J, Grothey A, Van Cutsem E. et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 2021; 39 (04) 273-284
163 Xie H, Wei L, Liu M. et al. The value of carcinoembryonic antigen stage in staging, prognosis, and management of colorectal cancer: results from two cohort studies. Front Oncol 2023; 13: 1268783
164 Hall C, Clarke L, Pal A. et al. A review of the role of carcinoembryonic antigen in clinical practice. Ann Coloproctol 2019; 35 (06) 294-305
165 Safety announcement: FDA highlights importance of DPD deficiency discussions with patients prior to capecitabine or 5FU treatment. FDA [Internet]. 2025 Jan 24 [cited 2025 Jan 29]. Accessed May 13, 2025 at: fda.gov/drugs/resources-information-approved-drugs/safety-announcement-fda-highlights-importance-dpd-deficiency-discussions-patients-prior-capecitabine
166 Amstutz U, Henricks LM, Offer SM. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018; 103 (02) 210-216
167 Patil VM, Noronha V, Joshi A. et al. Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?. South Asian J Cancer 2016; 5 (04) 182-185
168 Sahu A, Ramaswamy A, Ostwal V. Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience. J Gastrointest Oncol 2016; 7 (03) 380-386
169 Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020; 20 (11) 651-668
170 Meriggi F, Zaniboni A, Zaltieri A. Low-dose immunotherapy: Is it just an illusion?. Biomedicines 2023; 11 (04) 1032